中泰化学(002092) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥11,522,740,492.94, a decrease of 50.82% compared to the same period last year[9]. - The net profit attributable to shareholders was ¥731,286,486.83, representing a significant increase of 514.48% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥672,921,845.94, up 411.23% from the previous year[9]. - The basic earnings per share for Q3 2021 was ¥0.3006, a 465.72% increase compared to the same period last year[9]. - The net profit for the period reached ¥2,701,565,778.65, a significant recovery from a net loss of ¥730,326,238.66 in the previous period, marking a turnaround of over 470%[43]. - The total profit amounted to ¥3,081,193,750.13, compared to a loss of ¥656,936,958.41 in the same period last year, indicating a strong performance improvement[43]. - Operating profit was reported at ¥3,055,908,378.15, a substantial increase from a loss of ¥647,098,451.66 previously[43]. - The company reported a net profit margin decline, with net profit not specified but indicated by the significant drop in operating revenue[40]. Assets and Liabilities - The total assets at the end of the reporting period were ¥74,275,941,951.33, reflecting a 13.76% increase from the end of the previous year[9]. - Total current assets as of September 30, 2021, were 4,670,984,491.53 CNY, down from 5,190,659,577.01 CNY at the end of 2020[31]. - Current assets increased to CNY 25,290,302,544.71, up 21.8% from CNY 20,857,963,246.88 year-over-year[34]. - Non-current assets totaled CNY 48,985,639,406.62, reflecting a growth of 10.4% compared to CNY 44,436,260,280.12 in the previous year[34]. - Total liabilities decreased to CNY 43,234,467,427.23, down 1.2% from CNY 43,769,873,183.40[39]. - Total liabilities stood at ¥43,769,873,183.40, unchanged from the previous reporting period[62]. Cash Flow - The company reported a net cash flow from operating activities of ¥1,459,567,952.23 for the year-to-date, down 60.84% compared to the previous year[9]. - The company reported a net decrease in cash and cash equivalents of 301,365,948.75 CNY, a decline of 202.99% compared to the previous year[24]. - The net cash flow generated from operating activities was ¥1,459,567,952.23, a decline from ¥3,727,472,964.32 in the same period last year, showing a decrease of about 60.8%[49]. - Cash outflow from investment activities totaled ¥3,541,527,614.06, an increase of 47.2% compared to ¥2,403,756,626.78 in the previous period[53]. - Net cash flow from financing activities was ¥1,360,878,170.56, a significant recovery from a net outflow of ¥1,155,590,468.41 in the previous period[53]. Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥25,042,098,279.50, an increase of 32.26% year-on-year[9]. - The company had 92,171 common shareholders at the end of the reporting period[24]. - The largest shareholder, Xinjiang Zhongtai (Group) Co., Ltd., holds 19.46% of the shares, totaling 501,302,124 shares[24]. - Total equity attributable to the parent company is approximately CNY 18.93 billion[65]. - Total equity including minority interests amounts to approximately CNY 21.52 billion[65]. Investment and R&D - Research and development expenses increased by 226.14% to 43,761,160.38 CNY, indicating a significant investment in innovation[24]. - The company recorded investment income of ¥344,729,476.95, a significant increase from ¥46,745,092.39 in the prior period, reflecting improved investment performance[43]. Strategic Focus - The company is focusing on market expansion and new product development as part of its future strategy[38]. - The company completed the acquisition of a 40% stake in Xinjiang Zhongtai New Xin Chemical Technology Co., Ltd., making it a subsidiary[9].